Nuevos resultados de #DAPACKD La dapaglifozina reduce el riesgo de fallo renal y mejora la supervivencia en enfermedad renal diabética y no diabética, con y sin insuficiencia cardíaca. Seguimos con buenas noticias...
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
RT @ATRIUMRx: Exciting new data from DAPA-CKD trial published in @JACCJournals revealed that dapagliflozin reduces risk of kidney failure a…
RT @DrRaniKhatib: Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CK…
RT @DrRaniKhatib: Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CK…
Exciting new data from DAPA-CKD trial published in @JACCJournals revealed that dapagliflozin reduces risk of kidney failure and CVD/HF hospitalization in those with or without T2DM or HF. #CardioTwitter https://t.co/uudc3B54KN https://t.co/4MPDTCefsx
RT @DrRaniKhatib: Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CK…
RT @scaganefe: Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CKD p…
RT @scaganefe: Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CKD p…
Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CKD patients with or without type 2 diabetes, independent of HF. https://t.co/FwEKzQ2E2Z @canyucelkarabay @alikaragozmd @drsedd @cardioce
Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CKD patients with or without type 2 diabetes, independently of history of HF. https://t.co/agkARhJabo
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failure and cardiovascular death/HF hospitalisation…..and prolongs survival, independently of history of HF. https://t.co/R7iHB1w4nC
RT @UoGHeartFailure: Now online in @JACCJournals #JACCHF ahead of presentation at @escardio #ESC2021 Effects of Dapagliflozin in Patients…
RT @UoGHeartFailure: Now online in @JACCJournals #JACCHF ahead of presentation at @escardio #ESC2021 Effects of Dapagliflozin in Patients…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
Un estudio que sí cambiará la práctica clínica diaria…
RT @UoGHeartFailure: Now online in @JACCJournals #JACCHF ahead of presentation at @escardio #ESC2021 Effects of Dapagliflozin in Patients…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
#SGLT2 inhibitors initially effective as oral hypoglycemic agents, then for the treatment of #HF , regardless of the presence of diabetes, and now also for #CKD What's next? RT @JTLLERGO #CardioEd #CardioTwitter @escardio @SIAC_cardio @ACCinTouch @secardio
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @UoGHeartFailure: Now online in @JACCJournals #JACCHF ahead of presentation at @escardio #ESC2021 Effects of Dapagliflozin in Patients…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @coconnormd: Effects of Dapagliflozin in Pts with CKD, with and w/o HF;JACC:HF:JJ McMurray presents at ESC new benefits of Dapa in pts…
Espectacular los iSGLT2, previa a EMPEROR- preserved 🤩
Ya palpitando el congreso #ESCCongress se está lanzando con todo! 🙌#SGLT2i sirven para ✅ #T2DM ✅ #CKD ✅ #HFrEF ✅ #HFpEF
RT @UoGHeartFailure: Now online in @JACCJournals #JACCHF ahead of presentation at @escardio #ESC2021 Effects of Dapagliflozin in Patients…
RT @coconnormd: Effects of Dapagliflozin in Pts with CKD, with and w/o HF;JACC:HF:JJ McMurray presents at ESC new benefits of Dapa in pts…
RT @coconnormd: Effects of Dapagliflozin in Pts with CKD, with and w/o HF;JACC:HF:JJ McMurray presents at ESC new benefits of Dapa in pts…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
【SGLT2-iによるCKD例の心腎保護作用はHF合併の有無を 問わず?:DAPA-CKD追加解析/ JACC HF】 CKD [±2型DM] 4304例ランダム化:11.0%がHF合併。SGLT2阻害薬群における「腎機能低下・心腎死亡」、CV死亡・HF入院」減少作用はいずれも、HF合併の有無に有意な影響を受けず。 https://t.co/1A3Ew2G0s2
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @UoGHeartFailure: Now online in @JACCJournals #JACCHF ahead of presentation at @escardio #ESC2021 Effects of Dapagliflozin in Patients…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @UoGHeartFailure: Now online in @JACCJournals #JACCHF ahead of presentation at @escardio #ESC2021 Effects of Dapagliflozin in Patients…
Now online in @JACCJournals #JACCHF ahead of presentation at @escardio #ESC2021 Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure -> The benefits of dapagliflozin in DAPA-CKD were independent of a history of HF
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
RT @P_Rossing: Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals htt…
Effects of Dapagliflozin in Pts with CKD, with and w/o HF;JACC:HF:JJ McMurray presents at ESC new benefits of Dapa in pts with CKD w/wo HF on worsening renal disease+HFH+death.Big win for patients.@JJheart_doc @DukeHFDoc @mfiuzat https://t.co/Te7l
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
Wonder about the effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure? @jaccjournals https://t.co/BQazFPUwra @Stenodiabetes @JACCJournals https://t.co/FEcTJ1I5k1
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD patients: ✅ With or without type 2 diabetes‼️ ✅ Independently of history of HF‼️ @secardiologia @almucastro01 https://t.co/yY